NIAID VIROLOGY QUALITY ASSURANCE (VQA) COVID-19

NIAID病毒学质量保证（VQA）计划的目的是为NIAID资助的多地点临床研究的受试者样本进行HIV和其他病毒性病原体的病毒学检测提供全面的质量评估计划。VQA计划通过向实验室提供能力测试面板和实时分析运行控制，并分析每个实验室的能力测试面板和分析运行数据，确保从niaid支持的临床试验和艾滋病毒自然史研究中获得的病毒学实验室数据的有效性和实验室间和实验室内的可比性。VQA项目还实施现有和最先进的新病毒学分析的性能标准，开发和测试与分析相关的生物统计方法，并获取，测试，储存和分配质量控制材料和试剂。本项目支持SARS-CoV-2 （COVID-19）病毒学检测质量保证活动。

The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the validity and inter- and intra-laboratory comparability of virologic laboratory data obtained from NIAID-supported clinical trials and HIV natural history studies by providing laboratories with proficiency testing panels and real-time assay run controls and analyzing proficiency panel and assay run data from each laboratory. The VQA program also implements standards of performance for existing and state-of-the-art new virologic assays, develops and tests biostatistical methods relating to the assays, and acquires, tests, stores and dispenses quality control materials and reagents. Support under this project is for SARS-CoV-2 (COVID-19) virologic assay quality assurance activities.